At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 327 enrolled
Drug / intervention
risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
In Brief
A Phase 3 clinical trial evaluating risankizumab and secukinumab for Psoriasis. Completed, enrolled 327 participants across 61 sites in 9 countries.
Detailed Summary
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2018
Primary CompletionJul 2020
TodayJul 2026
First PostedMar 27, 2018
Enrollment StartMay 8, 2018
Primary CompletionJul 8, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.3 years ago
Interventions
risankizumabdrug
Subcutaneous (SC) injection
secukinumabdrug
Subcutaneous (SC) injection